Cellebrite DI (NASDAQ:CLBT) CMO Sells $24,705.52 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CMO David Nicholas Gee sold 2,198 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.24, for a total transaction of $24,705.52. Following the completion of the transaction, the chief marketing officer owned 139,604 shares in the company, valued at approximately $1,569,148.96. This trade represents a 1.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

David Nicholas Gee also recently made the following trade(s):

• On Monday, August 24th, David Nicholas Gee sold 4,323 shares of Cellebrite DI stock. The shares were sold at an average price of $11.36, for a total transaction of $49,109.28.
• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The stock was sold at an average price of $16.07, for a total value of $3,696.10.

Cellebrite DI Trading Up 2.9%

Shares of CLBT stock opened at $11.62 on Thursday. The stock has a market cap of $2.90 billion, a P/E ratio of 52.82, a P/E/G ratio of 1.73 and a beta of 1.18. The stock has a 50 day moving average of $14.19 and a 200 day moving average of $13.80. Cellebrite DI Ltd. has a twelve month low of $9.58 and a twelve month high of $19.98.

Cellebrite DI News Summary

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite launched the Portable Tactical Extraction Kit (C-TEK), a field-deployable digital-forensics solution for armed forces. The kit enables forward-deployed teams to rapidly triage data from phones, SIM cards, drones and portable media, expanding Cellebrite’s addressable market in defense and battlefield intelligence. C-TEK launch announcement
• Positive Sentiment: The announcement reinforces Cellebrite’s positioning as a provider of AI-enabled digital investigation and intelligence tools for governments, law enforcement and enterprises. Any adoption by military customers could support longer-term revenue growth, although the release did not disclose contracts or financial targets.
• Neutral Sentiment: Analyst opinion remains broadly constructive, with five Buy ratings and one Sell rating and a consensus price target of $16.70. However, JPMorgan, DA Davidson, Lake Street and Needham recently lowered their targets, signaling more cautious expectations after the stock’s decline.
• Neutral Sentiment: Reported short interest was zero shares, producing no meaningful short-interest signal. The data also contained an anomalous percentage-change figure, limiting its usefulness for assessing near-term trading pressure.
• Negative Sentiment: Kaplan Fox & Kilsheimer announced an investigation into potential securities-law violations involving Cellebrite. The announcement does not establish wrongdoing, but it adds legal, reputational and potential litigation risk that could weigh on investor sentiment. Kaplan Fox investigation
• Negative Sentiment: Chief Marketing Officer David Nicholas Gee sold 4,323 shares for approximately $49,100, following a sale of 2,198 shares worth about $24,700 several days earlier. The latest transaction was made under a pre-arranged Rule 10b5-1 plan and leaves him with a substantial holding, but repeated executive sales may still pressure sentiment. Insider sale filing

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. DA Davidson cut their price objective on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. JPMorgan Chase & Co. cut their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Needham & Company LLC cut their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. Weiss Ratings lowered shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Finally, Lake Street Capital cut their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.70.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Cooper Creek Partners Management LLC acquired a new position in shares of Cellebrite DI in the third quarter worth $55,999,000. Capital International Investors purchased a new position in Cellebrite DI in the fourth quarter valued at $41,073,000. Invesco Ltd. grew its stake in Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares in the last quarter. California State Teachers Retirement System grew its stake in Cellebrite DI by 1,595.2% during the 2nd quarter. California State Teachers Retirement System now owns 1,972,752 shares of the company’s stock worth $28,802,000 after purchasing an additional 1,856,378 shares in the last quarter. Finally, Weiss Asset Management LP increased its holdings in Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after purchasing an additional 1,846,851 shares during the period. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.